# SARS-CoV-2 Antibodies Based IVIG Therapy for COVID-19 Patients

> **NCT04521309** · PHASE1,PHASE2 · COMPLETED · sponsor: **Dow University of Health Sciences** · enrollment: 50 (actual)

## Conditions studied

- COVID-19

## Interventions

- **BIOLOGICAL:** SARS-CoV-2 antibody based IVIG therapy

## Key facts

- **NCT ID:** NCT04521309
- **Lead sponsor:** Dow University of Health Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-06-19
- **Primary completion:** 2021-01-26
- **Final completion:** 2021-02-08
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2021-03-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04521309

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04521309, "SARS-CoV-2 Antibodies Based IVIG Therapy for COVID-19 Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04521309. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*